Analyst consensus rating
Citius Oncology Analyst Rating: Buy
CTOR is rated Buy by 1 analysts with a $4.00 target. As of 2026-08-21.
Direct answer
Citius Oncology's consensus rating is Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.00.
Forecast evidence checked August 21, 2026.
Get free Citius Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.76
- Average price target
- $4.00
- High price target
- $4.00
- Low price target
- $4.00
- Low target gap
- +426.9%
- Target upside
- +426.9%
- High target gap
- +426.9%
- Target range width
- 0%
- Consensus rating
- Buy
- Analysts
- 1
- Evidence date
- August 21, 2026
- Valid through
- August 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Citius Oncology?
Citius Oncology has a verified Buy consensus. The same dataset has an average price target of $4.00.
How far are Citius Oncology's low and high targets from the recorded price?
The low target implies +426.9%, while the high target implies +426.9%.
How many analysts are included in Citius Oncology's consensus?
The verified consensus includes 1 analysts.
How is Citius Oncology's target upside or downside calculated?
The average target of $4.00 is divided by the recorded price of $0.76, then one is subtracted to produce +426.9%. This does not guarantee a future return.
When was Citius Oncology's analyst forecast verified?
The data was verified on 2026-08-21. The dataset is valid through 2026-08-28.